文献速递脑血管病外科神经重症

替罗非班方案预防迟发性脑缺血:病例系列研究

Tirofiban Protocol Protects Against Delayed Cerebral Ischemia: A Case-Series Study.
PubMed 文献 · Neurosurgery · 2020-01-01

该病例系列研究评估动脉瘤性蛛网膜下腔出血(aSAH)患者接受替罗非班持续输注方案后迟发性脑缺血(DCI)的风险。

要点

  • DCI、高龄和术后症状性卒中为死亡的显著预测因素。

核心结论

  • 替罗非班方案可降低aSAH患者DCI风险,且未带来额外风险。

主要发现

  • DCI、高龄和术后症状性卒中为死亡的显著预测因素。
  • 替罗非班降低死亡风险,但关联无统计学显著性。

临床怎么用

  • 对接受支架辅助弹簧圈栓塞或血流导向装置治疗的aSAH患者,可考虑替罗非班持续输注方案以降低DCI风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has not been any effective prophylaxis for delayed cerebral ischemia delayed cerebral ischemia (DCI) since the introduction of nimodipine. Platelet inhibition may reduce the risk by preventing the formation of microthrombi. Tirofiban has been used as a single monotherapy bridge given its safety profile and controlled platelet inhibition. OBJECTIVE: To assess the risk of DCI in aneurysmal subarachnoid hemorrhages (aSAH) patients treated with the tirofiban protocol. METHODS: aSAH patients between December 2010 and March 2019 who were treated with stent assisted coiling or flow-diverting device were started on a continuous tirofiban infusion protocol and were compared with patients who underwent coil embolization without antiplatelet therapy. Safety analysis was performed to assess DCI, hemorrhagic, and ischemic events. RESULTS: A total of 21 patients were included in the tirofiban series and 81 in the control group. There was no statistical difference in age, gender, Hunt-Hess grade, and Fisher scale between the 2 groups except for a higher Fisher grade II in the tirofiban group. Multivariate analysis revealed tirofiban to reduce the risk of vasospasm by 72 percent (OR .28, P = .03), without affecting the risk of hemorrhagic complications (OR = 0.50, P = .26). Tirofiban reduced the risk of symptomatic stroke endovascular procedure but it did not reach significance (P = .06). DCI, older age, and postprocedural symptomatic stroke were significant predictors of mortality. Tirofiban reduced the mortality risk, but this association was not statistically significant. CONCLUSION: The tirofiban protocol in aSAH patients reduces the risk of DCI without conferring additional risks. This supports previous findings were antiplatelet therapy reduced DCI in human and animal models.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Zanaty M, Osorno-Cruz C, Byer S, et al. Tirofiban Protocol Protects Against Delayed Cerebral Ischemia: A Case-Series Study. Neurosurgery. 2020. PMID: 32415850. doi:10.1093/neuros/nyaa170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。